zanubrutinib maintenance

DRUG2 trials

Sponsors

Sun Yat-sen University, The First Affiliated Hospital of Soochow University

Conditions

Mantle Cell LymphomaNewly-diagnosed Mantle Cell LymphomaUntreated Mantle Cell Lymphoma

Phase 2

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

Active, not recruitingNCT04624958

Sun Yat-sen UniversityMantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma

Start: 2020-12-01End: 2026-12-31Updated: 2024-10-18

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

The First Affiliated Hospital of Soochow UniversityUntreated Mantle Cell Lymphoma

Start: 2020-07-27End: 2025-07-26Target: 20Updated: 2022-08-17

Related Papers

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial

Nature Communications2026-03-28

Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.

Journal of Clinical Oncology2024-06-01

Zr Study: A Prospective Phase II Study of Zanubrutinib-Rituximab Chemo-Free Therapy with or without Autologous Stem Cell Transplantation in Newly Diagnosed Mantle Cell Lymphoma

Blood2023-11-022 citations

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA

HemaSphere2023-08-011 citations